PTGXProtagonist Therapeutics, Inc.

$6B

Q3 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$13M+216.7% YoY

Gross Profit

$13M100.0% margin

Operating Income

-$8M-59.3% margin

Net Income

-$8M-59.2% margin

EPS (Diluted)

$-0.21

QoQ Revenue Growth

+110.9%

Cash Flow

Operating Cash Flow

-$16M

Free Cash Flow

-$16M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$217M

Total Liabilities

$48M

Stockholders' Equity

$170M

Cash & Equivalents

$84M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$13M	$4M	+216.7%
Gross Profit	$13M	$4M	+216.7%
Operating Income	-$8M	-$17M	+54.7%
Net Income	-$8M	-$16M	+52.7%

Revenue Segments

License And Collaborative Revenue

$99M99%

Financial Service Other

$500,0001%

PTGX Q3 2020 Earnings — Protagonist Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena